Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT01516840

First Posted: January 25, 2012

Last Update Posted: January 18, 2017

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Collaborator:

Janssen Scientific Affairs, LLC

Information provided by (Responsible Party):

Bayer

Purpose

The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of two different dosages of rivaroxaban in the treatment of deep vein thrombosis (DVT) and the prevention of the occurrence and the recurrence of DVT or pulmonary embolism (PE) in Japanese patients with acute symptomatic DVT without symptomatic PE.

Condition	Intervention	Phase
Deep Vein Thrombosis	Drug: Rivaroxaban (Xarelto, BAY59-7939) Drug: Unfractionated heparin Drug: Warfarin	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment
Official Title:	Randomized, Open-label (Double Blind Among Rivaroxaban Groups in the Initial 3 Weeks), Parallel-group, Active-controlled Study of Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis Without Symptomatic Pulmonary Embolism

Resource links provided by NLM:

MedlinePlus related topics: Blood Clots Deep Vein Thrombosis

U.S. FDA Resources

Further study details as provided by Bayer:

Primary Outcome Measures:

Number of participants with newly onset of symptomatic venous thromboembolism (VTE) [ Time Frame: Up to 12 months ]
Number of clinically relevant bleedings [ Time Frame: Up to 2 days after last dose ]

Secondary Outcome Measures:

Number of participants with improvement in thrombotic burden [ Time Frame: At week 3 ]
Number of participants with deterioration in thrombotic burden [ Time Frame: Up to 12 months ]
Number of participants with the composite of newly onset of symptomatic VTE or asymptomatic deterioration of thrombus [ Time Frame: Up to 12 months ]


Enrollment:	60
Study Start Date:	March 2012
Study Completion Date:	January 2014
Primary Completion Date:	December 2013 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Arm 1	Drug: Rivaroxaban (Xarelto, BAY59-7939) 10 mg twice daily for 21 days, followed by 15 mg once daily
Experimental: Arm 2	Drug: Rivaroxaban (Xarelto, BAY59-7939) 15 mg twice daily for 21 days, followed by 15 mg once daily
Active Comparator: Arm 3	Drug: Unfractionated heparin To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
Active Comparator: Arm 4	Drug: Warfarin To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)

Detailed Description:

The general design of the trial is open label between the Rivaroxaban and the reference arm. However, there are two groups in the Rivaroxaban arm only for the initial 3 weeks. Between these two groups and in this initial period, the study is blinded.

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	20 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Men and women >/= 20 years of age in patients with confirmed acute symptomatic proximal deep vein thrombosis (DVT) without symptomatic pulmonary embolism (PE)

Exclusion Criteria:

Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT
More than 48 hours pre-randomization treatment with therapeutic dosages of anti-coagulant treatment or more than a single dose of warfarin from the onset of the current episode of DVT to randomization
Calculated creatinine clearance (CLCR) < 30 mL/min
Subjects with hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk
Active bleeding or high risk for bleeding contraindicating treatment with unfractioned Heparin (UFH) or warfarin
Systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01516840

Locations


Japan

Toyoake, Aichi, Japan, 470-1192

Sakura, Chiba, Japan, 285-8741

Maebashi, Gunma, Japan, 371-8511

Otake, Hiroshima, Japan, 739-0696

Sapporo, Hokkaido, Japan, 006-8555

Takarazuka, Hyogo, Japan, 665-0827

Kahoku-gun, Ishikawa, Japan, 920-0293

Kanazawa, Ishikawa, Japan, 920-8650

Yokohama, Kanagawa, Japan, 245-8575

Tsu, Mie, Japan, 514-8507

Sasebo, Nagasaki, Japan, 857-8511

Osakasayama, Osaka, Japan, 589-8511

Suita, Osaka, Japan, 565-8565

Bunkyo-ku, Tokyo, Japan, 113-8655

Chuoku, Tokyo, Japan, 104-8560

Itabashi-ku, Tokyo, Japan, 173-8610

Meguro-ku, Tokyo, Japan, 152-8902

Shinagawa, Tokyo, Japan, 141-8625

Shinjuku-ku, Tokyo, Japan, 162-8655

Aomori, Japan, 030-8553

Fukuoka, Japan, 810-0001

Kumamoto, Japan, 862-8505

Niigata, Japan, 951-8520

Okayama, Japan, 701-1192

Osaka, Japan, 530-8480

Osaka, Japan, 537-8511

Shizuoka, Japan, 424-8636

Tokushima, Japan, 770-8503

Wakayama, Japan, 640-8158

Sponsors and Collaborators

Bayer

Janssen Scientific Affairs, LLC

Investigators


Study Director:	Bayer Study Director	Bayer

More Information

Additional Information:

Click here and search for drug information provided by the FDA. This link exits the ClinicalTrials.gov site

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product. This link exits the ClinicalTrials.gov site

Click here to find results for studies related to Bayer Healthcare products. This link exits the ClinicalTrials.gov site

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Matsuo H, Prins M, Lensing AW, Fujinuma EW, Miyamoto Y, Kajikawa M. Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Curr Med Res Opin. 2015 Jun;31(6):1057-61. doi: 10.1185/03007995.2015.1037728. Epub 2015 May 11.

Yamada N, Hirayama A, Maeda H, Sakagami S, Shikata H, Prins MH, Lensing AW, Kato M, Onuma J, Miyamoto Y, Iekushi K, Kajikawa M. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program. Thromb J. 2015 Jan 17;13:2. doi: 10.1186/s12959-015-0035-3. eCollection 2015. Erratum in: Thromb J. 2016;14:11.


Responsible Party:	Bayer
ClinicalTrials.gov Identifier:	NCT01516840 History of Changes
Other Study ID Numbers:	14568
First Submitted:	January 20, 2012
First Posted:	January 25, 2012
Last Update Posted:	January 18, 2017
Last Verified:	January 2017

Keywords provided by Bayer:


acute symptomatic deep vein thrombosis

Additional relevant MeSH terms:


Thrombosis Venous Thromboembolism Venous Thrombosis Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Thromboembolism Calcium heparin Heparin Warfarin	Rivaroxaban Anticoagulants Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors

To Top